Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

Medipharm Labs Corp > Also keep in focus the NDA (new drug application) cos' we
View:
Post by subaru1i on Dec 06, 2023 4:51pm

Also keep in focus the NDA (new drug application) cos' we

have NO IDEA what the application of that drug will be for and we know one thing, it is NOT a generic which typically comes with lower margins.   Will the momentum indicator keep the uptrend going tomorrow?  If it does I will post screen shot of it here.   Institutionals, ala ITG Virtu are skinning uninformed retail shareholders alive for the moment and getting a pile of litterally free shares.  

alleyeonme...my disclosure...just over 1.5 million shares, TFSA stuffed to the max and sleeping very well at night as well.   The current b.s. is worth the 'weight'.
Comment by subaru1 on Dec 06, 2023 8:17pm
Where the hell you can se a momentum, Labs is moving sideways since over a year.  
Comment by alleyesonme on Dec 06, 2023 8:39pm
Yeah, it's frustrating..look at Danny deadlocks 40pg report..the business of medipharm labs has significant, numerous momentous events..regulatory drivers in our international markets continue to push triple digit YOY market growth...eventually all this will translate to the financials...business momentum doesn't always translate to stock price momentum..at some point it will fly.   ...more  
Comment by alleyesonme on Dec 06, 2023 8:22pm
Yes, generics are cheaper..I continue repeating..Epidiolex, pure cannabidol, a.k.a CBD..no different than LABS CBD 100 oil cost insurers between 1700-2200 usd...if the generic has half this price it represents 10-15x the current sell price of our CBD 100 oil...plenty of gravy to split with our partner...VERY lucrative..I do agree it's likely the NEW DRUG APPLICATION will be approved for ...more  
Comment by subaru1 on Dec 06, 2023 8:44pm
I have to agree with you the only active ingredient in Epidiolex is the Cannabidol, this means that Medipharm has already an Epidiolex generic, this sound unreal, nowhere i read that someone is taking CD100 to help softenig his epilectic problem, have you any proof of that.
Comment by subaru1i on Dec 06, 2023 8:55pm
Looks like you skipped out too many chemistry classes in high school.  Do you not understand what a molecule is?   If you don't get that, then you shouldn't be in the stock market at all because you have difficulty with your level of comprehension and just make yourself look like a board fool.   Maybe you have memory problems so let me remind you, the DMF LABS ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities